Related Experiment Video
Updated: Aug 13, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Effect of landomycin E on expression of mRNA coding for transforming growth factor beta ligands and specific
R Panchuk1, A Korynevska, R Stoika
1Institute of Cell Biology, NAS of Ukraine, Lviv 79005, Ukraine.
Unlabelled:
The aim of the present study was to investigate regulation of mRNA, coding for TGFbeta ligands and specific receptors, by novel antitumor antibiotic landomycin E (LE) in human breast adenocarcinoma cells of MCF-7 line, sensitive and resistant to anti-cancer agent doxorubicin.
Methods:
Semi-quantitative analysis of mRNA expression was estimated using RT-PCR and DNA gel-electrophoresis methods. For comparison, another anti-cancer drug doxorubicin (adriamycin) was utilized. THE RESULTS obtained indicate that LE induces up-regulation of mRNA coding for TGFbeta receptors type I and type II in MCF-7 cells, as well as in their doxorubicin-resistant sub-line.
Conclusion:
Anti-tumor action of LE may be mediated by TGFbeta, and a signaling pathway of this cytokine is not affected by the development of tumor cell resistance to doxorubicin.
Insights
The novel antitumor antibiotic landomycin E (LE) up-regulates TGFbeta receptors in breast cancer cells, including doxorubicin-resistant lines. This suggests LE
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Breast adenocarcinoma cells (MCF-7) are a model for studying anti-cancer drug resistance.
- Doxorubicin resistance is a significant challenge in breast cancer treatment.
- Transforming growth factor beta (TGFbeta) signaling plays a role in cancer progression and treatment response.
Purpose of the Study:
- To investigate the effect of landomycin E (LE) on mRNA expression of TGFbeta ligands and receptors in human breast adenocarcinoma MCF-7 cells.
- To compare the effects of LE with doxorubicin in sensitive and doxorubicin-resistant MCF-7 cells.
Main Methods:
- Semi-quantitative analysis of mRNA expression using RT-PCR.
- DNA gel electrophoresis.
- Utilized doxorubicin (adriamycin) as a comparative anti-cancer drug.
Main Results:
- Landomycin E (LE) induces up-regulation of mRNA for TGFbeta receptors type I and type II.
- This up-regulation was observed in both doxorubicin-sensitive and doxorubicin-resistant MCF-7 cells.
- The effects of LE were distinct from those of doxorubicin.
Conclusions:
- The anti-tumor action of landomycin E (LE) may be mediated by the TGFbeta signaling pathway.
- Tumor cell resistance to doxorubicin does not affect the TGFbeta signaling pathway targeted by LE.
- LE shows potential as an anti-cancer agent, even in drug-resistant breast cancer models.
